Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia

Kinoshita,Takashi; Azuma,Koichi; Sasada,Tetsuro; Okamoto,Masaki; Hattori,Satoshi; Imamura,Youhei; Yamada,Kazuhiko; Tajiri,Morihiro; Yoshida,Tsukasa; Zaizen,Yoshiaki; Kawahara,Akihiko; Fujimoto,Kiminori; Hoshino,Tomoaki

doi:10.3892/ol.2012.753

September 2012 Volume 4 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September 2012 Volume 4 Issue 3

Full Size Image

Article

Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia

Authors:
- Takashi Kinoshita
- Koichi Azuma
- Tetsuro Sasada
- Masaki Okamoto
- Satoshi Hattori
- Youhei Imamura
- Kazuhiko Yamada
- Morihiro Tajiri
- Tsukasa Yoshida
- Yoshiaki Zaizen
- Akihiko Kawahara
- Kiminori Fujimoto
- Tomoaki Hoshino
View Affiliations / Copyright

Affiliations: Department of Internal Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan, Biostatistics Center, Kurume University, Kurume, Japan, Department of Diagnostic Pathology, Kurume University School of Medicine, Kurume, Japan, Department of Radiology, Kurume University School of Medicine, Kurume, Japan
Pages: 477-482
|
Published online on: June 12, 2012

https://doi.org/10.3892/ol.2012.753
Expand metrics +

Abstract

Idiopathic interstitial pneumonia (IIP) is considered to be one of the risk factors for lung cancer (LC). However, therapeutic options for patients with LC complicated by IIP are not well established. In this study, we investigated the feasibility and efficacy of chemotherapy for patients with non-small cell lung cancer (NSCLC) complicated by IIP (NSCLC-IIP). We retrospectively analyzed 22 NSCLC-IIP patients who received chemotherapy. To determine how IIP affected the clinical outcomes in NSCLC, they were compared with 276 NSCLC patients without IIP, who were treated with chemotherapy alone. The response rate (partial response + stable disease) was 72.3% (17/22), whereas the incidence of acute exacerbation (AE) was 13.6% (3/22) in NSCLC-IIP patients treated with chemotherapy. NSCLC-IIP patients had significantly shorter survival compared with NSCLC patients without IIP (P<0.001) following chemotherapy, although the response rates to chemotherapy were not significantly different between the two groups. Multivariate analysis demonstrated that, in NSCLC patients receiving chemotherapy, IIP was a significantly unfavorable factor for progression-free and overall survival. Despite similar response rates to chemotherapy, NSCLC-IIP patients showed poorer prognosis than NSCLC patients without IIP, possibly due to the natural course of IIP. Chemotherapy may be a feasible option for NSCLC-IIP, if the risks of adverse effects are acceptable.

View Figures

View References

1	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer. 37(Suppl 8): S4–S66. 2001.PubMed/NCBI
2	Turner-Warwick M, Lebowits M, Burrows B and Johnson A: Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 35:496–499. 1980. View Article : Google Scholar : PubMed/NCBI
3	American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 165:277–304. 2002.
4	Katzenstein AL and Myers JL: Idiopathic pulmonary fibrosis. clinical relevance of pathologic classification. Am J Respir Crit Care Med. 157:1301–1315. 1998. View Article : Google Scholar : PubMed/NCBI
5	Kawasaki H, Nagai K, Yokose T, et al: Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 76:53–57. 2001. View Article : Google Scholar : PubMed/NCBI
6	Park J, Kim DS, Shim TS, et al: Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 17:1216–1219. 2001. View Article : Google Scholar : PubMed/NCBI
7	Aubry MC, Myers JL, Douglas WW, et al: Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 77:763–770. 2002. View Article : Google Scholar : PubMed/NCBI
8	Collard HR, Moore BB, Flaherty KR, et al: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 176:636–643. 2007. View Article : Google Scholar : PubMed/NCBI
9	Agarwal R and Jindal SK: Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. Eur J Intern Med. 19:227–235. 2008. View Article : Google Scholar : PubMed/NCBI
10	Minegishi Y, Sudoh J, Kuribayashi H, et al: The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kim DS, Park JH, Park BK, Lee JS, Nicholson AG and Colby T: Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 27:143–150. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kenmotsu H, Naito T, Kimura M, et al: The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 6:1242–1246. 2011. View Article : Google Scholar : PubMed/NCBI
13	Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh H and Hizawa N: Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal. 24:295–299. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia

This article is mentioned in:

Abstract

Figure 1

Related Articles